A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis

被引：2

作者：

Lyles, Laine ^{[1
]}

Farmer, Reagan ^{[2
]}

Abougergi, Marwan ^{[3
]}

机构：

[1] Univ South Carolina, Prisma Hlth, Columbia, SC 29208 USA

[2] Univ South Carolina, Sch Med Columbia, Columbia, SC USA

[3] Catalyst Med Consulting, Simpsonville, SC USA

来源：

ACG CASE REPORTS JOURNAL | 2023年 / 10卷 / 09期

关键词：

autoimmune hepatitis; drug-induced autoimmune hepatitis; check point inhibitor; chemotherapy; renal cell carcinoma; hepatitis; drug induced liver injury; steroid refractory; tocilizumab; nivolumab; ipilimumab; CANCER;

D O I：

10.14309/crj.0000000000001162

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Immune checkpoint inhibitors are becoming more commonly used for many forms of malignancy. With this class of medications being more heavily used, there has been an associated rise in medication-induced autoimmune hepatitis. This case involves a 35-year-old woman being treated with nivolumab/ipilimumab for renal cell carcinoma who developed a steroid-refractory autoimmune hepatitis.

引用

页数：3

共 50 条

[1] A Potential New Use for Tocilizumab: A Case of Refractory Checkpoint Inhibitor Hepatitis
Lyles, Laine A.
Farmer, Reagan
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S2082 - S2083
[2] Use of tocilizumab for the treatment of steroid and mycophenolate-refractory hepatitis and cholangiohepatitis induced by immune checkpoint inhibitor immunotherapy
Ling, Sophia
Jayathilaka, Bishma
Hui, Chee
Segal, Jonathan
Trinh, Andrew
JOURNAL OF HEPATOLOGY, 2024, 80 : S92 - S93
[3] Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
Doms, J.
Prior, J. O.
Peters, S.
Obeid, M.
ANNALS OF ONCOLOGY, 2020, 31 (09) : 1273 - 1275
[4] Tofacitinib is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis
Wang, Mike
Reynolds, Kerry L.
Montazeri, Kamaneh
Schaefer, Esperance A.
Sullivan, Ryan J.
Dougan, Michael
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (07) : 1539 - 1541
[5] Tocilizumab for Corticosteroid-Refractory Immune Checkpoint Inhibitor-Induced Generalized Morphea
Blaise, Manon
Cardot-Leccia, Nathalie
Seitz-Polski, Barbara
Picard-Gauci, Alexandra
Bertold, Clemence
Passeron, Thierry
Montaudie, Henri
JAMA DERMATOLOGY, 2023, 159 (01) : 112 - 114
[6] PREDICTORS AND OUTCOMES OF STEROID-REFRACTORY IMMUNE CHECKPOINT INHIBITOR HEPATITIS
Li, Michael
Sack, Jordan
Rahma, Osama E.
Grover, Shilpa
Zucker, Stephen D.
HEPATOLOGY, 2020, 72 : 85A - 85A
[7] Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature
Ali, Syed B.
Vembar, Preethi
Sukumaran, Shawgi
Gunawardane, Dimuth
Hughes, Tiffany
Smith, Anthony
IMMUNOTHERAPY, 2023, 15 (14) : 1125 - 1132
[8] Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis
Moi, Laura
Bouchaab, Hasna
Mederos, Nuria
Nguyen-Ngoc, Tu
Perreau, Matthieu
Fenwick, Craig
Vaucher, Julien
Sempoux, Christine
Peters, Solange
Obeid, Michel
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : 318 - 326
[9] CYTOKINE RELEASE STORM FOLLOWING IMMUNE CHECKPOINT INHIBITOR USE MANAGED WITH TOCILIZUMAB IN THE ICU
Covert, Erin
Mucha, Simon
Funchain, Paulime
CRITICAL CARE MEDICINE, 2023, 51 (01) : 162 - 162
[10] Potential radiotherapy-related reactivation of immune checkpoint inhibitor hepatitis
Yesmembetov, Kakharman
Sahin, Cennet
Murad, Mohamad
Berres, Marie-Luise
Koch, Alexander
von Websky, Martin
Vondran, Florian
Bruners, Philipp
Eble, Michael
Mohamed, Ahmed Allam
STRAHLENTHERAPIE UND ONKOLOGIE, 2025,

← 1 2 3 4 5 →